Chapel Hill startup with ties to UNC lands rights to drug offering hope to cystic fibrosis patients

Posted Oct 27, 2019
Path BioAnalytics (PBA), a precision medicine startup with ties to UNC, has scored the rights to a new drug therapy offering hope to cystic fibrosis (CF) patients with rare mutations. PBA is a graduate of Launch Chapel Hill, an accelerator program based in Chapel Hill, as well as the Kenan Flagler Business School program Startup UNC. (WRAL Tech Wire)

Related: Campus Connections

Former UNC Basketball Players Mourn Changes in Chapel Hill: 'It's Not Franklin Street Anymore'
Gone are beloved Chapel Hill staples like The Rathskeller, Schoolkids Records, Bub O'Malley's, Pepper's, Spanky's, and others that served generations of UNC students along Franklin...
Thu Jul 16, 2026

Chapel Hill-Carrboro Openings, Closings and Moves in April-June 2026
After the sign for the former military surplus store Surplus Sids was taken in March, it unceremoniously reappeared on June 10 — leaned up against...
Wed Jul 15, 2026

UNC Alumni Contribute $30.1 Billion to State’s Economy
In every corner of North Carolina, Tar Heels are leaving a large financial footprint. Alumni contributed a minimum of $30.1 billion in economic activity across...
Tue Jul 14, 2026

Al’s Burger Shack Hailed as ‘Best Cheeseburger in North Carolina’
The website Fast Food Club named Al’s Burger Shack in Chapel Hill as the best cheeseburger in North Carolina in a new list, which sought...
Sat Jul 11, 2026